At Big Ten CRC, Patricia A. Robinson, MD, discussed institutional and cooperative group strategies that have improved representation in oncology clinical trials.

At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used together in oncology.

Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.

Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast radiation therapy, practice implications, and next steps in capsular contracture research.

Nikolai Strusberg, MD, explained the clinical hypothyroidism endpoint and how thyroid dose should guide proton vs photon choice in breast cancer.

Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.

Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.

Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.